mRNA Vaccine and Therapeutics Market (2026) | R&D Investments, Personalized Vaccines, AI Drug Design, RNA Technology & Biotech Growth

DataM Intelligence has released a new research report titled "mRNA Vaccine and Therapeutics Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global mRNA Vaccine and Therapeutics market.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/mrna-vaccine-and-therapeutics-market?kb

mRNA vaccine and therapeutics market continues to evolve rapidly, driven by advancements in biotechnology, expanding clinical applications, and increasing investments in next-generation medicine.

United States: Recent Industry Developments
✅ February 2026: Moderna expanded its mRNA pipeline with new personalized cancer vaccine trials, strengthening its oncology portfolio.

✅ January 2026: Pfizer, in collaboration with BioNTech, advanced next-generation mRNA-based influenza vaccines into late-stage clinical trials.

✅ December 2025: Arcturus Therapeutics progressed its self-amplifying mRNA (saRNA) platform for infectious disease vaccines, enhancing dose efficiency and scalability.

List of Key Players 2026:

Azra Al, CureMetrix, Inc., ConcertAI, Immunai, MVision AI Inc., Paige AI, Inc., Mindpeak GmbH, Imagene AI Ltd., Predictive Oncology, and Tempus

Growth Forecast Projected 2026:

The Global mRNA Vaccine and Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Key Developments 2025-2026:

✅ February 2026: Market leaders advanced late-stage clinical trials for mRNA-based therapeutics targeting oncology and rare diseases, expanding beyond infectious disease applications.

✅ January 2026: Companies strengthened manufacturing capabilities by scaling up lipid nanoparticle (LNP) delivery systems and improving cold-chain logistics for global distribution.

✅ December 2025: Increased strategic collaborations between biotech firms and pharmaceutical companies accelerated pipeline development for personalized mRNA cancer vaccines.

✅ November 2025: Regulatory bodies supported faster approvals through adaptive frameworks, encouraging innovation in mRNA-based drug development and clinical testing.

✅ October 2025: Integration of AI and bioinformatics enhanced mRNA sequence design, improving efficacy, stability, and targeted delivery of therapeutics.

✅ In January 2025, Esphera SynBio launched a project to enhance mRNA vaccine effectiveness by enabling cells to produce modified nanomedicines, improving precision and therapeutic outcomes.

How Our Market Research Process Works:

The global mRNA Vaccine and Therapeutics Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the mRNA Vaccine and Therapeutics ecosystem.

Recent Mergers & Acquisitions (M & A) 2025-2026:

• March 2026 - Moderna agreed up to $2.25B settlement with Arbutus Biopharma & Genevant Sciences, securing freedom to operate mRNA technology without future royalties

• March 2026 - BioNTech SE announced creation of a new mRNA-focused company (with founders) involving transfer of mRNA assets and minority stake strategic spin-off to accelerate next-gen therapeutics

• January 2026 - BioNTech SE completed acquisition of CureVac, integrating R&D and manufacturing capabilities for oncology-focused mRNA therapies

• June 2025 - BioNTech SE acquired CureVac for $1.25B (all-stock deal) to strengthen mRNA-based cancer immunotherapy pipeline

Request Strategic Market Customization: https://datamintelligence.com/customize/mrna-vaccine-and-therapeutics-market?kb

Japan: Recent Industry Developments
✅ February 2026: Daiichi Sankyo accelerated development of mRNA vaccines targeting emerging infectious diseases, supported by government funding initiatives.

✅ January 2026: Takeda Pharmaceutical expanded partnerships to co-develop mRNA-based therapies, focusing on rare diseases and oncology applications.

✅ December 2025: Shionogi & Co., Ltd. strengthened R&D capabilities in nucleic acid therapeutics, including mRNA platforms for next-generation vaccines.

Major Focused Key Segmentations 2026:

By Product Type: Prophylactic Vaccines, Therapeutic Vaccines, Therapeutic Drugs

By Application: Cancer, Infectious Diseases, Rare Genetic Diseases, Others

By End-user: Hospitals & Clinics, Research Organizations, Academic Institutes, Others

Regional Growth Analysis for Market:

⇥ North America: Leads the global market, driven by strong R&D investments, advanced biotech infrastructure, and rapid adoption of mRNA-based vaccines and therapeutics.

⇥ Asia-Pacific (including Japan): Fastest-growing region supported by expanding biotech capabilities, government initiatives, and increasing vaccine production capacity.

⇥ Europe: Significant growth fueled by regulatory support, rising clinical trials, and strong presence of pharmaceutical innovators.

⇥ Middle East & Africa: Emerging market driven by improving healthcare infrastructure, vaccine access initiatives, and growing focus on biotechnology advancements.

We Provide Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=mrna-vaccine-and-therapeutics-market?kb

FAQ

Q1: What is the current size of the mRNA Vaccine and Therapeutics Market?

A: The mRNA Vaccine and Therapeutics Market was valued at US$ 46.32 Billion in 2024 and is forecasted to hit US$ 200.11 Billion by 2033

Q2: How rapidly will the Market expanding?

A: The mRNA Vaccine and Therapeutics market is projected to grow at a CAGR of 18.4% between 2025 and 2033.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.